X-box binding protein 1 (XBP1), CD138 (Syndecan-1) and CS1 (SLAMF7) are highly expressed antigens in cancers including multiple myeloma (MM). Here, we identify and characterize immunogenic HLA-A24 peptides derived from these antigens for potential vaccination therapy of HLA-A24+ patients with MM. The identified immunogenic HLA-A24-specific XBP1 unspliced (UN) [185][186][187][188][189][190][191][192][193] 
INTRODUCTION
Multiple myeloma (MM) is characterized by proliferation of plasma cells within the bone marrow, elevated serum and/or urine monoclonal protein, and clinical sequelae including hypercalcemia, renal dysfunction, anemia, bone disease and immune suppression.
1,2 Despite recent treatment advances using novel targeted immune agents, relapse is common and new treatment strategies are urgently needed. 3 Immunotherapeutic approaches can provide durable immune responses in the MM patients; however, there are multiple obstacles to development of a successful immunotherapy for MM including tumor heterogeneity, ongoing DNA damage and clonal evolution, multiple tumor escape mechanisms and compromised immune cell function in patients. Specifically, induction of dendritic cell dysfunction, defects in B-cell and T-cell immunity, decreased responsiveness to IL-2, reduced T-cell cytotoxic activity and expansion of myeloidderived suppressor cells is hallmarks of MM pathogenesis. [4] [5] [6] [7] These immune defects may account, at least in part, for the failure of recent immunotherapy trials.
Vaccine therapies in MM to date have most commonly been patient-specific, using dendritic cells pulsed with tumor-specific idiotype or tumor lysates, 8, 9 which are both costly and laborintensive. To overcome this limitation, we and others have developed alternative approaches using tumor-associated antigen-specific cancer vaccines. Among them, peptide-based vaccines have multiple advantages including broad applicability, ready detection of antigen-specific immune responses, feasibility of combining multiple target antigens, as well as ease and cost of manufacturing. Vaccination using immunogenic peptides with affinities to various MHC Class I molecules; therefore, may offer a more broadly applicable novel vaccine-based strategy.
In previous studies, we identified immunogenic peptides derived from the XBP1 (X-box binding protein 1), CD138 (Syndecan-1) and CS1 (SLAMF7), which are associated with MM pathogenesis and are highly expressed on the tumor cells, and reported on the generation and application of the antigen-specific CTL. [10] [11] [12] We first identified HLA-A2-restricted peptides from these antigens, since HLA-A2 is the most dominant MHC Class I molecule, present in 50% of the patient population in North America. To expand the patient population and overcome the HLA-A2 restriction, we have developed a new immunotherapeutic option to treat patients expressing HLA-A24, which is the second most dominant MHC Class I in North America, as well as the most frequent MHC Class I in Asia. Here, we report on the identification of novel HLA-A24 specific peptides derived from the unspliced (UN) and spliced isoforms of XBP1, CD138 and CS1 antigens, and demonstrate their capacity to elicit CD3 + CD8
+ antigen-specific CTL as single or as a cocktail of four immunogenic peptides. These antigen-specific CTL displayed distinct phenotype profiles and anti-tumor activities against HLA-A24 + MM cells. Importantly the anti-MM activities were enhanced within the central memory and effector memory subsets of the ex vivo generated multipeptide- Figure 1 . Identification of HLA-A24 specific XBP1, CD138 and CS1 peptides. Supplementary Figure 1 . HLA-A24-binding affinity of the XBP1, CD138 and CS1 peptides at high peptide concentration. T2-A24 cells were pulsed overnight with a high dose of respective peptide (200 μg/ ml) in serum-free AIM-V medium. HLA-A24 specific HIV-1 envelope protein gp41 583-591 (RYLKDQQLL) peptide was used as the positive control. Following incubation, the cells were harvested, washed and stained with HLA-A24-PE mAb for flow cytometric analyses. Among 24 candidate peptides screened, XBP1 UN [12] [13] [14] [15] [16] [17] [18] [19] [20] 
had the highest HLA-A24 binding affinities. Peptide affinity to HLA-A24 molecules is shown as an increase in specific HLA-A24-PE mean fluorescence intensity (MFI) in the peptide binding assays (average ± s.e.; N = 5). (a-c) HLA-A24 binding affinity of the XBP1, CD138 and CS1 peptides at low peptide concentrations. T2-A24 cells were pulsed overnight at lower concentrations (12.5 μg/ml, 25 μg/ml, 50 μg/ml, 100 μg/ml) of respective peptide in serum-free AIM-V medium. Following incubation, the cells were harvested, washed and stained with HLA-A24-PE mAb for flow cytometric analyses. XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] 
displayed the highest levels of HLA-A24 binding affinity at all the concentrations tested. Peptide affinity to HLA-A24 is shown as an increase in the specific HLA-A24-PE mean fluorescence intensity (MFI) in the peptide-binding assays (average ± s.e.; N = 5).
specific CTL, and could be further increased by treatment with immune modulators, checkpoint inhibitors or immune agonists. These studies provide the framework for use of a cocktail of four immunogenic HLA-A24-specific peptides as a cancer vaccine to treat HLA-A24 + patients with MM or other cancers.
METHODS

Synthetic peptides
Identified HLA-A24 specific peptides derived from full-length XBP1 UN, XBP1 spliced, CD138 (Syndecan-1) and CS1 (SLAMF7) proteins were synthesized by standard fmoc (9-fluorenylmethyl-oxycarbonyl) chemistry, purified to 495% using reverse-phase chromatography and validated by mass-spectrometry for molecular weight (Biosynthesis, Lewisville, TX, USA ; CD138 − ) obtained from ATCC were used as MHC HLA-A24 matched antigen-specific negative control cell lines. All cell lines were authenticated by short tandem repeat profiling, tested for mycoplasma contamination and cultured in RPMI-1640 or DMEM medium (Gibco-Life Technologies) supplemented with 10% fetal calf serum (BioWhittaker, Walkersville, MD, USA), 100 IU/ml penicillin and 100 μg/ml streptomycin (Gibco-Life Technologies).
Reagents
Fluorochrome conjugated mouse anti-human CD3, CD4, CD8, CD45RO, CCR7, CD28, CD38, CD40L, CD45RO, CD69, CD107a, Granzyme B, Perforin, IFN-γ, TNF-α, 41BB (CD137), CTLA-4, PD-1, TIM-3, LAG-3, VISTA and HLA-A24 monoclonal antibodies were purchased from Becton Dickinson (BD) Pharmingen or BD Biosciences (San Diego, CA, USA). Recombinant human GM-CSF was obtained from Immunex (Seattle, WA, USA), and recombinant human IL-2, IL-4, IFN-α and TNF-α were purchased from R&D Systems (Minneapolis, MN, USA).
HLA-A24 peptide affinity assay HLA-A24-specific binding for each peptide was evaluated by flow cytometry using the T2-A24 cell line. In the assay, T2-A24 cells were washed in serum-free AIM-V medium and resuspended to a final concentration of 1 × 10 6 cells/ml. The cells were pulsed with various concentrations (0-200 μg/ml) of respective UN XBP1, spliced XBP1, CD138 or CS1 peptide, or with a control HIV-1 envelope protein gp41 583-591 peptide (50 μg/ml) plus human β2-microglobulin (3 μg/ml) (Sigma), and then incubated at 26~28°C in 5% CO 2 humidified air. Following overnight incubation, the cells were washed in PBS (Gibco-BRL) containing 5% fetal calf serum, stained with mouse anti-human HLA-A24-PE mAb, and analyzed using a FACSCanto flow cytometer. HLA-A24 peptide-binding affinity was determined by measuring the level of upregulation of HLA-A24 molecules on the T2-A24 cells induced by specific and stable peptide binding. HLA-A24 peptide-binding affinity is reported as the median fluorescence intensity (MFI) of HLA-A24 expression and the results are shown as the mean MFI ± s.e. We have tested N = 5 for testing the HLA-A24-specific affinity of each peptide.
Induction of HLA-A24 individual peptide-specific CTL or multipeptide-specific CTL HLA-A24 specific XBP1 unspliced (UN) or XBP1 spliced (SP) peptide-specific CTL (XBP1 UN-CTL or XBP1 SP-CTL), CD138 peptide-specific CTL (CD138-CTL), CS1 peptide-specific CTL (CS1-CTL) or the multipeptide-specific CTL (MP-CTL) were generated ex vivo by repeated stimulation of enriched CD3 HLA-A24 peptide-specific CTL proliferation and functional activities in response to myeloma cell lines
To evaluate HLA-A24-restricted CTL proliferation, CFSE (Molecular Probes, Eugene, OR, USA) labeled HLA-A24 peptide-specific CTL were co-incubated with irradiated (20 Gy) HLA-A A24 + or HLA-A24 -myeloma cell lines. On days 5 and 7, the cultures were harvested, stained with fluorochrome conjugated anti-CD3 and anti-CD8 mAbs, and analyzed by flow cytometry to determine specific CD3 + CD8
+ CTL proliferation to MM cells. The functional anti-tumor activities of each respective HLA-A24 peptidespecific CTL or HLA-A24 multipeptide-specific CTL was assessed and analyzed (N = 5) by CD107a degranulation, granzyme B and perforin production, and IFN-γ/IL-2/TNF-α cytokine production in response to myeloma cells. Antigen-specific CTL were co-incubated with myeloma cells in the presence of anti-CD107a mAb. After 1 h co-culture of effector and target cells, a cocktail of Brefeldin A and Monensin (BD was added, and the cultures were incubated an additional 5 h. Cells were then harvested, washed and stained with mAbs specific to cell surface antigens including CD3, CD8, CD45RO, CCR7 and 41BB. The cells were washed, fixed and permeabilized, and stained with mAb specific to granzyme B, perforin, IFN-γ, IL-2 or TNF-α. Cells were acquired and analyzed using a LSRII Fortessa flow cytometer and DIVA v8.0 software. [185] [186] [187] [188] [189] [190] [191] [192] [193] 
RESULTS
High binding affinities of XBP1 UN
The full-length amino-acid sequences of UN or spliced XBP1, CD138 and CS1 proteins were examined using the search software NetMHC, SYFPEITHI, IEDB and MHCBN databases, followed by the BIMAS and NetCTL programs to select potential high affinity HLA-A24 nanomer peptides with extended half-time disassociation rates, proteasomal C-terminal cleavage, and TAP transport. A total Identification of HLA-A24 peptides for multiple myeloma J Bae et al of seven peptides from UN XBP1 protein, four peptides from spliced XBP1, seven peptides from CD138 protein and six peptides from CS1 protein were selected for synthesis and evaluation of HLA-A24 affinity and stability (Supplementary Table) . Individual peptides were initially screened at a high peptide concentration (200 μg/ml) to select those with an HLA-A24 binding affinity greater than or similar to the HLA-A24-specific HIV-1 envelope protein gp41 583-591 (RYLKDQQLL) control peptide (Supplementary Figure 1) . Among those screened, a total of eight peptides were subsequently selected for further evaluation at lower peptide concentrations (12.5, 25, 50, 100 μg/ml) as follows; XBP1 UN [12] [13] [14] [15] [16] [17] [18] [19] [20] ( N = 3; Figure 1a ). Among the XBP1 UN peptides, XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] (I S P W I L A V L) showed a higher affinity than XBP1 UN [12] [13] [14] [15] [16] [17] [18] [19] [20] 
In addition, CD138 265-273 (I F A V C L V G F) peptide had a greater HLA-A24 affinity (*P o 0.05) than either the CD138 [21] [22] [23] [24] [25] [26] [27] [28] [29] 
peptide at all of the peptide concentrations (N = 3; Figure 1b) . Finally, the CS1 240-248 (L F V L G L F L W) peptide showed a higher level of HLA-A24 affinity (*P o 0.05) at each of the low peptide concentrations and a slightly higher level of HLA-A24 affinity than CS1 321-329 (T M P D T P R L F) peptide (N = 3; Figure 1c ). Based on these results, we chose the peptides with the highest HLA-A24 specific binding affinity, XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] Generation of CD3 + CD8 + CTL by repeated stimulation of T cells with HLA-A24-specific XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] 
Individual antigen-specific CTL were generated by repeated stimulation of HLA-A24 + normal donors' enriched CD3 + T lymphocytes (N = 5) with the selected XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] 
+ T-cell subset showed a gradual increase above baseline levels after each round of individual HLA-A24 specific peptide stimulation; XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] Phenotypic characterization of multipeptide-specific CTL generated with a cocktail of HLA-A24 specific XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] 
We next evaluated the ability of a cocktail of these four HLA-A24 peptides to induce multipeptide-specific CTL with antimyeloma effects. The multipeptide-specific CTL displayed increased expression of critical T-cell markers including CD28, CD40L, 41BB, CD38 and CD69 (Figure 5a ). We also observed increased checkpoint molecule expression on the multipeptidespecific CTL, as compared with the control T cells without multipeptide stimulation. Specifically, we observed high expression levels of PD-1, TIM-3 and LAG-3 on the multipeptide-specific CTL (Figure 5b ). In contrast, CTLA-4 or VISTA expression was lower Figure 4 . Continued
Identification of HLA-A24 peptides for multiple myelomaon the multipeptide-specific CTL. Next, we evaluated the functional activities of the multipeptide-specific CTL against myeloma cells. The multipeptide-specific CTL consistently demonstrated increased perforin, IFN-γ, IL-2 and TNF-α production in response to HLA-A24 + KMS11 myeloma cells (Figure 5c ), supporting the use of a cocktail of the four HLA-A24 peptides to evoke multipeptide-specific CTL with poly-functional activities against myeloma cells.
Characterization of central memory and effector memory CD8 + CTL generated by HLA-A24 XBP1/CD138/CS1 multipeptide Following HLA-A24 multipeptide stimulation, the multipeptidespecific CTL (N = 5) were evaluated for their Naive:Memory T-cell subset profiles and anti-myeloma activities. Representative flow cytometric analyses of memory cell development from two HLA-A24 + individuals' after each round of multipeptide stimulation is shown in Figure 6a . We detected an increase in the central memory (CM; CD45RO + CCR7 + ) CTL population following two cycles of multipeptide stimulation (CM-Donor 1: 44%, Donor 2: 39%) and effector memory (EM; CD45RO + CCR7 -) population following three cycles of stimulation (EM-Donor 1: 24%, Donor 2: 18%) (Figure 6b ). With each additional cycle of HLA-A24 + XBP1/ CD138/CS1 multipeptide stimulation, the specific CTL showed further differentiation into EM CTL, with 480% of the multipeptide-specific CTL (N = 3) having the EM phenotype upon an additional cycle of peptides stimulation (Figure 6b ). The Naive: Memory cell subsets of multipeptide-specific CTL were also evaluated for their expression of specific activation or costimulatory markers after four cycles of multipeptide stimulation. We observed a high expression (frequency and MFI) of CD38 + cells in the CM, EM and TE subsets (Figure 6c ). High expression level of CD69, an early cell activation marker, was distinctly detected within the CM CTL subset, as were costimulatory CD40L and 41BB.
Functional anti-tumor activities within the central memory and effector memory cells induced by HLA-A24 XBP1/CD138/CS1 multipeptide Next, we evaluated anti-MM activities of the antigen-specific CTL subsets generated by HLA-A24-specific XBP1/CD138/CS1 multipeptide. The responses to myeloma was consistently highest within the CM subset, as shown by the production of perforin (71.1%) and Th1-type cytokines including IFN-γ (74.0%) and IL-2 (76.3%), as well as upregulation of the co-stimulatory marker 41BB (80.6%) compared with the EM subset (perforin: 8.8%, IFN-γ: 10.4%, IL-2: 16.5%, 41BB: 14.5%) and TE subset (perforin: 0.9%, IFN-γ: 1.3%, IL-2: 2.6%, 41BB: 3.3%) of the multipeptide-specific CTL (Figure 7a) . The functional activity of HLA-A24 multipeptidespecific CTL was significantly higher within the CM subset (460%, n = 3), followed by EM (420%) or TE 45%) as evidenced by their perforin upregulation, IFN-γ/IL-2 Th1 cytokines production and 41BB upregulation (Figure 7b) . Furthermore, we investigated the expression of various immune checkpoint molecules on the Naive: Memory subsets of multipeptide-specific CTL. Among the different CTL subsets, the CM cell subset showed the highest expression levels (% positive cells and MFI) of the most immune checkpoints evaluated, including CTLA-4, PD-1 and LAG-3 (Figure 7c ). Distinctively, TIM-3 was detected as the highest in its expression (% positive cells and MFI) in both EM and CM cell subsets.
DISCUSSION
Antigen-specific cancer vaccines elicit tumor-suppressive responses by targeting various tumor-associated antigens expressed on cancer cells. The discovery of novel immunogenic peptides from selected tumor-associated antigen offers new immunotherapeutic options, either as a vaccine or cell-based immunotherapy. A large number of clinical trials have demonstrated the immunogenicity of vaccines with minimal toxicities and low-side effects in cancer patients. 13, 14 Our group has identified and developed a peptide-based cancer vaccine targeting the highly over-expressed, XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) antigens, which have been implicated in MM pathogenesis. Specifically, we previously reported on novel immunogenic heteroclitic XBP1 unspliced (US) 184-192 (YISPWILAV), 10 heteroclitic XBP1 spliced (SP) 367-375 (YLFPQLISV) (10), native CD138 260-268 (GLVGLIFAV), 11 and native CS1 239-247 (SLFVLGLFL) 12 peptides specific to HLA-A2, which is the most dominant MHC Class I molecule in North America and second most dominant in Asia. The heteroclitic XBP1 peptides YISPWILAV and YLFPQLISV were designed to improve their HLA-A2 binding affinities than their originally identified native XBP1 US [184] [185] [186] [187] [188] [189] [190] [191] [192] (NISPWILAV) or XBP1 SP 367-375 (ELFPQLISV) peptides (10), in order to bypass tolerance and enhance the peptides immunogenicity against cancer cells. These previously identified XBP1/CD138/CS1 peptides, either individually or as a cocktail of four peptides, induced antigens-specific CTL with functional anti-tumor activities against HLA-A2 + MM cells. [10] [11] [12] 15, 16 A consideration that influences the success of vaccine trials includes selection of the appropriate patient population that can generate an effective immune response. Importantly, MM has the ability to elude immune surveillance through various mechanisms including induction of dendritic cell dysfunction, expansion of myeloid-derived suppressor cells, upregulation of checkpoint inhibitors like PD-L1 on MM cells and defects in B-cell immunity. [17] [18] [19] [20] [21] In addition, defects in T-cell function, including loss of tumor-specific effector T-cell activity and induction of Treg Figure 5 . Continued cells, as well as cytokines and growth factors including interleukin-6 (IL-6), macrophage inflammatory protein-1α, insulin-like growth factor-I, vascular endothelial growth factor and hepatocyte growth factor, contribute to compromised immune function and myeloma pathogenesis. 7, 22, 23 In ongoing efforts we are therefore vaccinating patients with early-stage smoldering multiple myeloma (SMM), who do not have compromised immunity owing to disease or therapy, with the goal of delaying or preventing progression to active MM. Importantly, a recently completed Phase I clinical trial using our previously described HLA-A2 multipeptide combination of XBP1, CD138 and CS1 peptides as a vaccine in SMM patients induced antigen-specific CD3 + CD8 + memory CTL with functional Th1-type immune responses (IFN-γ, IL-2, TNF-α). 24 In addition, the first Phase 2a trial using our HLA-A2 multipeptide vaccine in combination with an immune modulatory drug Lenalidomide demonstrated enhanced vaccine efficacy, evidenced by a higher induction of tetramer positive antigen-specific CTL and functional immune responses in HLA-A2 positive SMM patients. 24 Beyond myeloma, overexpression of the XBP1 and CD138 antigens are also seen in solid tumor cancers, including breast cancer, colon cancer and pancreatic cancer. 25, 26 The HLA-A2 multipeptide vaccine is also in clinical trials to treat the patients with triple negative breast cancer. 27 To expand the therapeutic opportunity in patients beyond HLA-A2 restriction, we report here on novel immunogenic peptides to treat patients expressing HLA-A24, the second most dominant MHC Class I molecule in North America and the most frequent MHC Class I molecule in Asia. HLA-A24-specific peptides derived from UN XBP1, spliced XBP1, CD138 or CS1 were identified and characterized as follows: XBP1 UN [185] [186] [187] [188] [189] [190] [191] [192] [193] . In addition, a cocktail of these four immunogenic HLA-A24 peptides elicited multipeptide-specific CTL with a robust immune response against a wide repertoire of the targeted tumor-associated antigen on myeloma cells. This multipeptide approach may therefore overcome the loss of specific CTL activity due to specific antigen mutation or deletion on tumor cells or defects in the T-cell repertoire, which limit single antigen-based vaccine approaches. Our results demonstrate that a cocktail of the four immunogenic HLA-A24 specific UN XBP1/spliced XBP1/CD138/CS1 peptides evoke multipeptide-specific CTL with distinct phenotypic profiles against HLA-A24 + myeloma cells including upregulation of costimulatory molecules (CD28, CD40L, 41BB), cellular activation markers (CD38, CD69) and immune functional activities (perforin upregulation, Th1-type cytokines production).
Memory CD8 + T cells are a critical component of protective immunity in many different types of diseases including cancer. Optimal cancer vaccine therapies require induction of an antigenspecific 'memory' CD8 + T-cell population, which can self-renew and respond effectively to tumor antigens, while providing persistent long-term anti-tumor immunity. [28] [29] [30] [31] [32] [33] Here, we provide evidence that repeated stimulation of CD3 + T cells with a cocktail of four HLA-A24 peptides specific to XBP1, CD138 and CS1 antigens evoke memory CD8 + CTL including central memory and effector memory cells. Among the HLA-A24 multipeptide-specific CTL Naive:Memory cell subsets, the central memory population showed the highest expression of key co-stimulatory and cellular activation markers including CD28, CD38 and 41BB. However, the antigens-specific central memory CTL also had the highest expression of immune checkpoints (CTLA-4, PD-1, LAG-3, TIM-3) as compared with the effector memory and terminal effector CD8 + CTL populations. Despite expression of immune checkpoint antigens, the central memory cells within the HLA-A24 + XBP1/ CD138/CS1 peptides-specific CTL retained the highest level of anti-MM activities. These observations suggest the possibility of increasing their functional activities with a blocking antibody against PD-1 or TIM-3, which were the main immune checkpoints induced following the multipeptide stimulation. Future studies will investigate the benefit of combining a checkpoint inhibitor(s) with the immunogenic HLA-A24 peptides to enhance anti-tumor activities by the antigens-specific CTL.
In summary, we have identified and validated novel immunogenic HLA-A24 peptides derived from XBP1 UN, XBP1 spliced, CD138 and CS1 antigens capable of inducing CD8 + CTL with robust anti-tumor activities against MM cells. These results highlight the potential therapeutic application of a cocktail of HLA-A24 XBP1un, XBP1sp, CD138 and CS1 peptides to evoke the antigens-specific CTL with a broad spectrum of responses against tumor. Combination approach to inhibit immune suppression and enhance the antigens-specific activities will be explored in our future studies. 
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